Guillain-Barre Syndrome Market To Reach $1,039.99 Million By 2030

Guillain-Barre Syndrome Market Growth & Trends

The global guillain-Barre syndrome market size is anticipated to reach USD 1,039.99 million by 2030 and is expected to expand at a CAGR of 6.10% during the forecast period, according to a new report by Grand View Research, Inc. The increasing prevalence of Guillain-Barré Syndrome (GBS), a rare but serious autoimmune disorder affecting the peripheral nervous system, is driving growth opportunities in the healthcare sector. Businesses can capitalize on this market expansion through advancements in treatment modalities, diagnostic tools, and patient care solutions. The demand for effective therapies such as Intravenous Immunoglobulin (IVIG) and Plasma Exchange is rising, necessitating improved access to these treatments via hospital and retail pharmacies.

GBS presents in multiple variants, each requiring specialized medical approaches. Acute Inflammatory Demyelinating Polyneuropathy (AIDP) is the most common form in North America and Europe, characterized by progressive muscle weakness and sensory disturbances. Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), a related but chronic condition, necessitates long-term management strategies, creating sustained demand for therapeutic interventions. Miller Fisher Syndrome (MFS), a rarer variant, primarily affects eye movement and coordination, necessitating targeted neurological treatments. Acute Motor Axonal Neuropathy (AMAN), more prevalent in Asia and Latin America, underscores the need for region-specific diagnostic and therapeutic developments.

Recent outbreaks of GBS, potentially linked to viral infections such as Zika and other emerging pathogens, have intensified market interest. A surge in cases drives the need for enhanced surveillance, early diagnosis, and timely therapeutic intervention, boosting investment in healthcare infrastructure. Governments and pharmaceutical companies are increasing research efforts to develop new treatment options and improve existing protocols. The outbreak-driven demand for IVIG and Plasma Exchange, primary treatments for GBS, has put pressure on global plasma supply chains, encouraging innovation in alternative therapies.

The COVID-19 pandemic has further impacted the GBS market, as studies have indicated a potential association between SARS-CoV-2 infection and an increased risk of GBS. The surge in COVID-19 cases led to a rise in reported GBS diagnoses, driving higher demand for IVIG and Plasma Exchange treatments. In addition, pandemic-related disruptions in healthcare supply chains have affected the availability of essential therapies, necessitating strategic adjustments in pharmaceutical production and distribution. Increased awareness and research into post-viral neurological complications have also propelled investment into GBS diagnostics and treatment innovations.

Treatment delivery methods are evolving, with both parenteral and oral options under exploration. While IVIG remains the gold standard for acute cases, research into oral immunomodulatory treatments is gaining momentum, potentially offering more accessible long-term management solutions for CIDP patients. Pharmacies play a crucial role in GBS treatment distribution. Hospital pharmacies dominate the market due to the need for inpatient care and close monitoring during IVIG or Plasma Exchange therapy. However, retail pharmacies are expanding their role in CIDP management, providing patients with convenient access to maintenance therapies and supportive medications.

With increasing awareness, evolving treatment approaches, and growing pharmaceutical investment, the GBS market is poised for significant growth. Innovations in both acute and chronic care solutions will continue to shape the landscape, creating new opportunities for businesses in healthcare, therapeutics.

 Request a free sample copy or view report summary: Guillain-Barre Syndrome Market Report

Guillain-Barre Syndrome Market Report Highlights

• Intravenous Immunoglobulin (IVIG) dominated the Guillain-Barré Syndrome (GBS) treatment market in 2024. This dominance is driven by IVIG’s proven efficacy in modulating the immune response, reducing disease progression, and improving recovery rates, making it the preferred first-line treatment for GBS.

• Acute Inflammatory Demyelinating Polyneuropathy (AIDP) held the largest market share among GBS subtypes in 2024. As the most common form of GBS, particularly in North America and Europe, AIDP's prevalence significantly influences the demand for effective therapeutic options, further strengthening its market dominance.

• Parenteral led the GBS treatment market in 2024. Given the critical nature of the disease, IV-administered treatments such as IVIG and plasma exchange ensure rapid and effective therapeutic action, enhancing patient outcomes in both acute and severe cases.

• Hospital pharmacies remained the dominant distribution channel in 2024. Due to the need for immediate medical intervention and specialized care, hospital pharmacies play a crucial role in ensuring the availability and administration of GBS treatments, particularly in acute care settings.

• North America led the GBS treatment market, attributed to factors such as a well-established healthcare infrastructure, high awareness of neurological disorders, and the availability of advanced treatment options. The region’s strong focus on research and innovation further supports market growth..

Guillain Barre Syndrome Market Segmentation

Grand View Research has segmented the Guillain-Barre syndrome (GBS) market on the basis of therapeutic, type, route of administration, distribution channel, and region:

Guillain Barre Syndrome Therapeutic Outlook (Revenue, USD Million, 2018 - 2030)

• Intravenous Immunoglobulin (IVIG)

• Plasma Exchange

• Others

Guillain Barre Syndrome Type Outlook (Revenue, USD Million, 2018 - 2030)

• Acute Inflammatory Demyelinating Polyneuropathy (AIDP)

• Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

• Miller Fisher Syndrome (MFS)

• Acute Motor Axonal Neuropathy (AMAN)

• Others

Guillain Barre Syndrome Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

• Parenteral

• Oral

Guillain Barre Syndrome Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacies

• Retail Pharmacies

• Other Pharmacies

Guillain Barre Syndrome Region Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Thailand

  • South Korea

  • Australia

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Guillain-Barre Syndrome Market

• AbbVie Inc.

• Biogen

• Cadila Pharmaceuticals

• CSL

• F. Hoffmann-La Roche Ltd.

• GSK plc

• Grifols S.A.

• LGM Pharma

• Merck & Co., Inc.

• Octapharma AG

• Pfizer Inc.

• Takeda Pharmaceutical Company Limited